SEARCH

SEARCH BY CITATION

References

  • 1
    Markmann JF, Gornbein J, Morkowitz JS, Levy MF, Klintmalm GB, Yersiz H, et al. A simple model to estimate survival after retransplantation of liver. Transplantation 1999; 647:422430.
  • 2
    Evans RW, Manninen DL, Dong FB. An economic analysis of liver transplantation costs, insurance coverage, and reimbursement. Adv Liver Transpl 1993; 22:451473.
  • 3
    Evans RW, Manninen DL, Dong FB, McLynne DA. Is retransplantation cost effective? Transplant Proc 1993; 25:16941697.
  • 4
    O'Grady JG. Clinical economics review: Liver transplantation. Aliment Pharmacol Ther 1997; 11:44551.
  • 5
    Rosen HR, Madden JP, Martin P. A model to predict survival following hepatic retransplantation. Hepatology 1999; 29:365389.
  • 6
    Wall WJ. Recurrent disease after liver transplantation, implications for the future. Liver Transplant Surg 1997; 6:362367.
  • 7
    Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202210.
  • 8
    Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51:248252.
  • 9
    Prieto M, Berenguer M, Rayon J, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29:250256.
  • 10
    Sheiner P, Schwartz M, Mor E, Schluger L, Theise N, Kishikawa K, et al. Severe and multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:3034.
  • 11
    Rosen H, Shackleton C, Higa L, Gralnek I, Farmer D, McDiarmid S, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:14531457.
  • 12
    Berenguer M, Prieto M, Palau A, Rayón JM, Carrasco D, San Juan F, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus–related graft cirrhosis. Liver Transpl 2003; 9:228235.
  • 13
    Ghobrial R, Farmer D, Baquerizo A, Colquhoun S, Rosen H, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999; 229:824831.
  • 14
    Yao FY, Bass NB, Hirose R, Terrault NA, Ascher NL, Roberts JP. Prediction of survival after liver re-transplantation based on pre-operative Child-Turcotte Pugh (CPT) score and the model foe end stage liver disease (MELD) score. Hepatology 2002; 36:228A.
  • 15
    Sheiner P, Schulger L, Emre S, Thung S, Lau J, Schwartz M, et al. Retransplantation for recurrent hepatitis C. Liver Transplant Surg 1997; 3:130136.
    Direct Link:
  • 16
    Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients. Liver Transpl 2000; 6:553561.
  • 17
    Facciuto M, Heidt D, Guarrera J, Bodian CA, Miller CM, Emre S, et al. Retransplantation for late liver graft failure: Predictors of mortality. Liver Transpl 2000; 6:174179.
  • 18
    Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66:16121616.
  • 19
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350355.
  • 20
    Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33:13551357.
  • 21
    Sheiner P, Boros P, Klion F, Thung S, Schluger L, Lau J, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831838.
  • 22
    Terrault NA, Khalil M, Bollinger K, Roberts JP, Ascher NL. Limitations in the use of prophylactic antiviral strategy in hepatitis C infected patients undergoing liver transplantation. Hepatology 2002; 36:177A.
  • 23
    Krawczynski K, Alter M, Tankersley D, Beach M, Robertson B, Lambert S, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173:822828.
  • 24
    Hinrichsen H, Benhamou Y, Reiser M, Sentjens R, Wedemeyer H, Hochshule M, et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 2002; 36:379A.